Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmicals 已獲得波士頓製藥公司一筆未公開的里程碑式付款，該款項基於給藥波士頓製藥公司贊助的 BOS-342（前身爲 PRS-342）的第 1/2 期研究中的第一位患者的給藥
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmicals 已獲得波士頓製藥公司一筆未公開的里程碑式付款，該款項基於給藥波士頓製藥公司贊助的 BOS-342（前身爲 PRS-342）的第 1/2 期研究中的第一位患者的給藥
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。